1. The challenges of using radiological ‘tumour response' as an outcome: lessons learned from neo-tango and artemis, two neo-adjuvant chemotherapy breast cancer trials
- Author
-
L Grybowicz, Anne-Laure Vallier, Clare Blenkinsop, Helen B Higgins, Janet A. Dunn, Helena M. Earl, and Louise Hiller
- Subjects
Target lesion ,Chemotherapy ,medicine.medical_specialty ,business.industry ,Clinical judgement ,medicine.medical_treatment ,Medicine (miscellaneous) ,Bioinformatics ,Tumour response ,medicine.disease ,Chemotherapy regimen ,Lesion ,Breast cancer ,Radiological weapon ,Poster Presentation ,medicine ,Pharmacology (medical) ,Radiology ,medicine.symptom ,business - Abstract
Methods Neo-tAnGo and ARTemis are national 800-patient breast cancer trials assessing neo-adjuvant chemotherapy regimens, both with a secondary endpoint of radiological tumour response, assessing treatment effect in terms of change in tumour size. Both trials record radiological sizes at baseline, mid-way through and at the end of the chemotherapy regimens. Neo-tAnGo (randomising Jan’05 to Sept’07) recorded mammograms and/or ultrasounds and/or MRI scans, identifying up to two breast and one axillary lesion as ‘target’ lesions. At each of the 3 time-points and for each target lesion, the scan types and largest diameters observed (maximum of two) were reported, along with a clinical judgement of response. ARTemis (randomising May’09 to Jan’13) recorded ultrasounds only, recording the longest single diameter of each tumour (including axillary tumours) along with total ‘tumour bulk’ in each breast. At midand endchemotherapy, a clinical judgement of response per breast is also recorded.
- Published
- 2013